Flash Finance

Procter & Gamble Health LimitedPGHLCorporate

Pharmaceuticals - Multinational Latest results: Dec 2025 2 quarters of data
Consolidated Standalone
₹5,200.00
MCap ₹8,632 Cr
Procter & Gamble Health Limited — Stock analysis & AI research Procter & Gamble Health Limited — Seasonality — best & worst months Procter & Gamble Health Limited — Technical indicators & charts Procter & Gamble Health Limited — Technical setup — score, trend, support & resistance Procter & Gamble Health Limited — Falling Wedge pattern forming Procter & Gamble Health Limited — Live exchange announcements
📋 High ROE Stocks📋 High ROCE Stocks📋 High Operating Margin Stocks📋 Low Debt Stocks📋 Quality Stocks📋 Quality Stocks Near 52-Week Low 📈 Death Cross Stocks📈 MACD Bullish Crossover📈 Multi-Timeframe Bearish Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹374 Cr
Sales · Dec 2025
₹110 Cr
Operating Profit · Dec 2025
29.5%
OPM % · Dec 2025
₹78 Cr
Net Profit · Dec 2025
₹46.74
EPS · Dec 2025

📝 Procter & Gamble Health Limited — results explained

Quarter ended December 2025 (Q3 FY26)

Procter & Gamble Health Limited reported revenue of ₹374 crore for the quarter ended December 2025 (Q3 FY26).

Net profit stood at ₹78 crore. Earnings per share (EPS) came in at ₹46.74.

Operating profit stood at ₹110 crore — an operating margin (OPM) of 29.5%.

Valuation snapshot

At the current price of ₹5,200.00, PGHL has a market capitalisation of ₹8,632 crore.

Within the Pharmaceuticals - Multinational industry, it is the largest of the 3 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 51.82%, foreign institutional investors (FIIs) 6.42%, domestic institutional investors (DIIs) 12.63%, public shareholders 29.13% of Procter & Gamble Health Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹8,632 Cr
Current Price ?
₹5,200.0
P/E ?
N/A
Industry P/E ?
24.10
P/B ?
16.44
P/S ?
N/A
P/FCF ?
26.72
Enterprise Value ?
₹8,641 Cr
EV/EBITDA ?
N/A
PEG ?
N/A
Earnings Yield ?
N/A
Dividend Yield ?
N/A
Profitability & Returns
Sales (TTM) ?
N/A
OPM ?
N/A
Profit after tax (TTM) ?
N/A
EPS (TTM) ?
N/A
ROCE ?
84.0%
ROE ?
N/A
ROA ?
N/A
Growth
Sales — latest qtr ?
₹374 Cr
PAT — latest qtr ?
₹78 Cr
YoY qtr sales growth ?
N/A
YoY qtr profit growth ?
N/A
Sales growth (3y) ?
N/A
Sales growth (5y) ?
N/A
Profit growth (3y) ?
N/A
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹9 Cr
Debt to Equity ?
0.02
Interest Coverage ?
N/A
Current Ratio ?
N/A
Ownership
Promoter holding ?
51.82%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
-23.5%
Return 6 months ?
3.5%

🗓️ Quarterly results (2 quarters · ₹ Cr)

same fiscal quarter as Dec bestweakest per row · for costs (interest, NPAs) low is best
Metric Jun 2024Dec 2025 YoY % QoQ %
Sales 284374 — —
Operating Profit 48110 — —
Other Income 24 — —
Interest 00 — —
Depreciation 76 — —
Profit Before Tax 23109 — —
Net Profit 1778 — —
EPS 10.1146.74 — —
OPM % 17.0% 29.5% — —

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric Jun 2023Jun 2024Mar 2025Mar 2026 % Chg
Equity Capital 17171717 +0.0%
Reserves 734522520508 -2.3%
Borrowings 121089 +12.5%
Other Liabilities 338247250308 +23.2%
Total Liabilities 1,101794794841 +5.9%
Fixed Assets 144128116102 -12.1%
CWIP 3261114 +27.3%
Investments 0000 —
Other Assets 925660667726 +8.8%
Total Assets 1,101794794841 +5.9%

💧 Cash Flow (latest 4 periods)

Metric Jun 2023Jun 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 236228169338 +100.0%
Cash from Investing Activity -22-7101 -90.0%
Cash from Financing Activity -98-418-235-344 -46.4%
Net Cash Flow 116-197-56-5 +91.1%
Free Cash Flow 198207168323 +92.3%
CFO/OP 100%102%78%97% +24.4%

➗ Ratios (latest 4 periods)

Metric Jun 2023Jun 2024Mar 2025Mar 2026 % Chg
Debtor Days 34275743 -24.6%
Inventory Days 136120152137 -9.9%
Days Payable 239184239192 -19.7%
Cash Conversion Cycle -69-37-30-13 +56.7%
Working Capital Days 15194830 -37.5%
ROCE % 45%45%48%84% +75.0%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 51.82%51.82%51.82%51.82%51.82%51.82% +0.0%
FIIs 6.99%7.24%6.97%6.20%6.33%6.42% +1.4%
DIIs 14.15%13.90%13.84%13.67%12.44%12.63% +1.5%
Public 27.03%27.05%27.37%28.30%29.42%29.13% -1.0%
No. of Shareholders 52,47850,00649,30250,88349,05650,426 +2.8%

⚖️ Peer comparison

Industry: Pharmaceuticals - Multinational · 3 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 PGHL Procter & Gamble ₹5,321.00 8,833 24.7 1,433 358 32.5% 25.0% 15.6% 30.8% 7.3% 45.7%
2 SANOFICONR Sanofi Consumer ₹3,650.00 8,418 31.6 950 266 37.2% 28.0% — — 6.7% 12.8%
3 SANOFI Sanofi India ₹2,928.60 6,745 20.8 1,805 324 26.7% 18.0% 16.4% 1.8% 7.8% 19.3%
❓ Frequently asked questions
What was Procter & Gamble Health Limited's revenue in Q3 FY26?
Procter & Gamble Health Limited reported revenue of ₹374 crore for the quarter ended December 2025 (Q3 FY26).
What was Procter & Gamble Health Limited's net profit in Q3 FY26?
Net profit stood at ₹78 crore. Earnings per share (EPS) came in at ₹46.74.
What is PGHL's market capitalisation and P/E ratio?
At the current price of ₹5,200.00, PGHL has a market capitalisation of ₹8,632 crore.
Who owns Procter & Gamble Health Limited? (shareholding pattern)
As of Sep 2026, promoters held 51.82%, foreign institutional investors (FIIs) 6.42%, domestic institutional investors (DIIs) 12.63%, public shareholders 29.13% of Procter & Gamble Health Limited.
TTM ends N/A. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI